- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04314401
National Cancer Institute "Cancer Moonshot Biobank"
Cancer Moonshot Biobank Research Protocol
This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. By looking at samples and information collected from the same people over time, researchers hope to better understand how cancer changes over time and over the course of medical treatments.
Studieoversikt
Status
Forhold
- Ondartet fast neoplasma
- Melanom
- Akutt myeloid leukemi
- Multippelt myelom
- Anatomisk stadium III brystkreft AJCC v8
- Anatomisk stadium IV brystkreft AJCC v8
- Egglederkarsinom
- Magekarsinom
- Ikke-småcellet lungekarsinom
- Stadium III lungekreft AJCC v8
- Stadium IV lungekreft AJCC v8
- Metastatisk prostatakarsinom
- Ovariekarsinom
- Esophageal karsinom
- Invasivt brystkarsinom
- Stage IVB prostatakreft AJCC v8
- Klinisk stadium IV gastrisk kreft AJCC v8
- Klinisk stadium IV Gastroøsofageal Junction Adenocarcinoma AJCC v8
- Trippel-negativt brystkarsinom
- Trinn IV tykktarmskreft AJCC v8
- Primært peritonealt karsinom
- Klinisk stadium IV Esophageal Adenocarcinoma AJCC v8
- Ovarial høygradig serøst adenokarsinom
- Fase III egglederkreft AJCC v8
- Stadium III Eggstokkreft AJCC v8
- Fase IV egglederkreft AJCC v8
- Stadium IV Eggstokkreft AJCC v8
- Hormonreseptorpositivt brystkarsinom
- Småcellet lungekarsinom
Detaljert beskrivelse
PRIMARY OBJECTIVE:
I. To support current and future investigations into drug resistance and sensitivity and other National Cancer Institute (NCI)-sponsored cancer research initiatives through the procurement and distribution of multiple longitudinal biospecimens and associated data from a diverse group of cancer patients who are undergoing standard of care treatment at NCI Community Oncology Research Program (NCORP) sites and other National Clinical Trials Network (NCTN) sites.
SECONDARY OBJECTIVES:
I. To provide a service of value to study participants and their medical providers through the performance of molecular profiling assays on tumor samples in a Clinical Laboratory Improvement Act (CLIA)-certified laboratory and reporting of results to physicians and patients that they may opt to use in clinical management, including analysis of data for acquired resistance mechanisms.
II. To enable the development of patient-derived models such as cell lines and xenografts for cancer researchers through the provision of biospecimens from up to 20% of study participants to the NCI's Patient Derived Models Repository (PDMR), a national resource available to investigators.
III. To develop and implement robust approaches in patient and provider engagement to improve understanding of biobanking and its relationship to cancer research and increase representation of minority and underserved study participants in cancer research.
IV. To develop increased capabilities in United States (U.S.) community hospitals and clinics for contribution to cancer research through biobanking activities.
V. To enable secondary research generated from the project through deposition of data in public repositories such as Cancer Research Data Commons (CRDC), The Cancer Imaging Archive (TCIA) and database of Genotypes and Phenotypes (dbGaP) and other potential NCI databases, including clinical, radiology and pathology data with an emphasis on treatment response and outcome data.
VI. To provide residual biospecimens and associated data from the project to the cancer research community.
OUTLINE:
Patients undergo collection of tissue samples during baseline and at time of disease progression and collection of blood samples throughout the study, including at time of disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected if available. Additionally, patients may undergo computed tomography (CT), positron emission tomography (PET)/CT and/or magnetic resonance imaging (MRI) throughout the study, and may undergo paracentesis on study. Patient medical records are reviewed, and data is collected for at least 5 years.
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiesteder
-
-
Alabama
-
Daphne, Alabama, Forente stater, 36526
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis
-
Fairhope, Alabama, Forente stater, 36532
- Thomas Hospital
-
Mobile, Alabama, Forente stater, 36607
- Mobile Infirmary Medical Center
-
Saraland, Alabama, Forente stater, 36571
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland
-
-
Arizona
-
Kingman, Arizona, Forente stater, 86401
- Kingman Regional Medical Center
-
-
Arkansas
-
Fort Smith, Arkansas, Forente stater, 72903
- Mercy Hospital Fort Smith
-
-
California
-
Arroyo Grande, California, Forente stater, 93420
- PCR Oncology
-
Bakersfield, California, Forente stater, 93301
- AIS Cancer Center at San Joaquin Community Hospital
-
Loma Linda, California, Forente stater, 92357
- Veterans Affairs Loma Linda Healthcare System
-
Salinas, California, Forente stater, 93901
- Salinas Valley Memorial
-
-
Colorado
-
Brighton, Colorado, Forente stater, 80601
- Intermountain Health Platte Valley Hospital
-
Denver, Colorado, Forente stater, 80218
- Saint Joseph Hospital - Cancer Centers of Colorado
-
Golden, Colorado, Forente stater, 80401
- Lutheran Hospital - Cancer Centers of Colorado
-
Grand Junction, Colorado, Forente stater, 81501
- Saint Mary's Hospital and Regional Medical Center
-
Lafayette, Colorado, Forente stater, 80026
- Good Samaritan Hospital - Cancer Centers of Colorado
-
-
Connecticut
-
Hartford, Connecticut, Forente stater, 06102
- Hartford Hospital
-
-
Delaware
-
Dover, Delaware, Forente stater, 19901
- Bayhealth Hospital Kent Campus
-
Milford, Delaware, Forente stater, 19963
- Bayhealth Hospital Sussex Campus
-
-
Florida
-
Boca Raton, Florida, Forente stater, 33486
- Boca Raton Regional Hospital
-
Deerfield Beach, Florida, Forente stater, 33064
- Broward Health North
-
Fort Lauderdale, Florida, Forente stater, 33316
- Broward Health Medical Center
-
Tampa, Florida, Forente stater, 33606
- Tampa General Hospital
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30342
- Northside Hospital
-
Savannah, Georgia, Forente stater, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Illinois
-
Bloomington, Illinois, Forente stater, 61704
- Illinois CancerCare-Bloomington
-
Chicago, Illinois, Forente stater, 60612
- John H Stroger Jr Hospital of Cook County
-
Chicago, Illinois, Forente stater, 60625
- Swedish Covenant Hospital
-
Danville, Illinois, Forente stater, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Forente stater, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Forente stater, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Evanston, Illinois, Forente stater, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg, Illinois, Forente stater, 61401
- Illinois CancerCare-Galesburg
-
Glenview, Illinois, Forente stater, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park, Illinois, Forente stater, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Mattoon, Illinois, Forente stater, 61938
- Carle Physician Group-Mattoon/Charleston
-
Mount Vernon, Illinois, Forente stater, 62864
- SSM Health Good Samaritan
-
Pekin, Illinois, Forente stater, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Forente stater, 61615
- Illinois CancerCare-Peoria
-
Urbana, Illinois, Forente stater, 61801
- Carle Cancer Center
-
Washington, Illinois, Forente stater, 61571
- Illinois CancerCare - Washington
-
-
Iowa
-
Ames, Iowa, Forente stater, 50010
- McFarland Clinic - Ames
-
Bettendorf, Iowa, Forente stater, 52722
- University of Iowa Healthcare Cancer Services Quad Cities
-
Cedar Rapids, Iowa, Forente stater, 52403
- Oncology Associates at Mercy Medical Center
-
Cedar Rapids, Iowa, Forente stater, 52402
- Physicians' Clinic of Iowa PC
-
Des Moines, Iowa, Forente stater, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Forente stater, 50309
- Blank Children's Hospital
-
Des Moines, Iowa, Forente stater, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Iowa City, Iowa, Forente stater, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, Forente stater, 70808
- Our Lady of the Lake Physician Group
-
New Orleans, Louisiana, Forente stater, 70118
- Children's Hospital New Orleans
-
New Orleans, Louisiana, Forente stater, 70112
- University Medical Center New Orleans
-
Shreveport, Louisiana, Forente stater, 71103
- LSU Health Sciences Center at Shreveport
-
-
Maine
-
Augusta, Maine, Forente stater, 04330
- Harold Alfond Center for Cancer Care
-
Belfast, Maine, Forente stater, 04915
- MaineHealth Waldo Hospital
-
Biddeford, Maine, Forente stater, 04005
- MaineHealth Maine Medical Center - Biddeford
-
Brunswick, Maine, Forente stater, 04011
- MaineHealth Cancer Care and IV Therapy - Brunswick
-
Brunswick, Maine, Forente stater, 04011
- Mid Coast Hospital
-
Damariscotta, Maine, Forente stater, 04543
- MaineHealth LincolnHealth Hospital
-
Farmington, Maine, Forente stater, 04938
- MaineHealth Franklin Hospital
-
Lewiston, Maine, Forente stater, 04240
- Saint Mary's Regional Medical Center
-
Norway, Maine, Forente stater, 04268
- MaineHealth Stephens Hospital
-
Portland, Maine, Forente stater, 04102
- Maine Medical Partners Surgical Care
-
Portland, Maine, Forente stater, 04102
- MMP Surgical Care Casco Bay
-
Portland, Maine, Forente stater, 04102
- MaineHealth Maine Medical Center - Portland
-
Rockport, Maine, Forente stater, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, Forente stater, 04073
- MaineHealth Cancer Care and IV Therapy - Sanford
-
Scarborough, Maine, Forente stater, 04074
- Maine Children's Cancer Program
-
Scarborough, Maine, Forente stater, 04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland, Maine, Forente stater, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
South Portland, Maine, Forente stater, 04106
- MaineHealth Urology - South Portland
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Forente stater, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Forente stater, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Forente stater, 48118
- Chelsea Hospital
-
Grand Rapids, Michigan, Forente stater, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Iron Mountain, Michigan, Forente stater, 49801
- Dickinson County Healthcare System
-
Livonia, Michigan, Forente stater, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, Forente stater, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
-
Missouri
-
Ballwin, Missouri, Forente stater, 63011
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Joplin, Missouri, Forente stater, 64804
- Freeman Health System
-
Joplin, Missouri, Forente stater, 64804
- Mercy Hospital Joplin
-
Rolla, Missouri, Forente stater, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla, Missouri, Forente stater, 65401
- Phelps Health Delbert Day Cancer Institute
-
Saint Joseph, Missouri, Forente stater, 64506
- Heartland Regional Medical Center
-
Springfield, Missouri, Forente stater, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Forente stater, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Forente stater, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Forente stater, 63109
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, Forente stater, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Forente stater, 63128
- Mercy Hospital South
-
Washington, Missouri, Forente stater, 63090
- Mercy Hospital Washington
-
-
Montana
-
Billings, Montana, Forente stater, 59102
- Saint Vincent Frontier Cancer Center
-
Butte, Montana, Forente stater, 59701
- Saint James Community Hospital and Cancer Treatment Center
-
-
Nebraska
-
Grand Island, Nebraska, Forente stater, 68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
-
Nevada
-
Carson City, Nevada, Forente stater, 89703
- Carson Tahoe Regional Medical Center
-
Las Vegas, Nevada, Forente stater, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Forente stater, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, Forente stater, 89144
- Comprehensive Cancer Centers of Nevada - Town Center
-
Las Vegas, Nevada, Forente stater, 89148
- Comprehensive Cancer Centers of Nevada
-
Las Vegas, Nevada, Forente stater, 89169
- Comprehensive Cancer Centers of Nevada - Central Valley
-
Las Vegas, Nevada, Forente stater, 89103
- Hope Cancer Care of Nevada
-
Las Vegas, Nevada, Forente stater, 89183
- OptumCare Cancer Care at Fort Apache
-
-
New Hampshire
-
Nashua, New Hampshire, Forente stater, 03060
- Saint Joseph Hospital
-
-
New Jersey
-
Morristown, New Jersey, Forente stater, 07960
- Morristown Medical Center
-
Newton, New Jersey, Forente stater, 07860
- Newton Medical Center
-
Pompton, New Jersey, Forente stater, 07444
- Chilton Medical Center
-
Summit, New Jersey, Forente stater, 07902
- Overlook Hospital
-
-
New York
-
New York, New York, Forente stater, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
The Bronx, New York, Forente stater, 10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx, New York, Forente stater, 10467
- Children's Hospital at Montefiore
-
The Bronx, New York, Forente stater, 10467
- Montefiore Medical Center - Moses Campus
-
The Bronx, New York, Forente stater, 10461
- Montefiore Medical Center-Weiler Hospital
-
-
North Carolina
-
Charlotte, North Carolina, Forente stater, 28204
- Novant Health Presbyterian Medical Center
-
Greenville, North Carolina, Forente stater, 27834
- East Carolina University
-
Greenville, North Carolina, Forente stater, 27834
- ECU Health Medical Center
-
Kernersville, North Carolina, Forente stater, 27284
- Novant Health Cancer Institute - Kernersville
-
Kinston, North Carolina, Forente stater, 28501
- ECU Health Oncology Kinston
-
Mount Airy, North Carolina, Forente stater, 27030
- Novant Health Cancer Institute - Mount Airy
-
Pinehurst, North Carolina, Forente stater, 28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Thomasville, North Carolina, Forente stater, 27360
- Novant Health Cancer Institute - Thomasville
-
Washington, North Carolina, Forente stater, 27889
- Marion L Shepard Cancer Center - ECU Health Beaufort Hospital
-
Winston-Salem, North Carolina, Forente stater, 27103
- Novant Health Forsyth Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73120
- Mercy Hospital Oklahoma City
-
-
Rhode Island
-
Providence, Rhode Island, Forente stater, 02908
- Roger Williams Medical Center
-
-
South Carolina
-
Columbia, South Carolina, Forente stater, 29203
- Prisma Health Richland Hospital
-
Columbia, South Carolina, Forente stater, 29220
- Prisma Health Baptist Hospital
-
Gaffney, South Carolina, Forente stater, 29341
- Gibbs Cancer Center-Gaffney
-
Greenville, South Carolina, Forente stater, 29605
- Prisma Health Greenville Memorial Hospital
-
Greer, South Carolina, Forente stater, 29651
- Gibbs Cancer Center-Pelham
-
Spartanburg, South Carolina, Forente stater, 29303
- Spartanburg Medical Center
-
Union, South Carolina, Forente stater, 29379
- SMC Center for Hematology Oncology Union
-
-
Texas
-
San Antonio, Texas, Forente stater, 78229
- Audie L Murphy VA Hospital
-
-
Virginia
-
Lynchburg, Virginia, Forente stater, 24501
- Centra Alan B Pearson Regional Cancer Center
-
Richmond, Virginia, Forente stater, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Forente stater, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Renton, Washington, Forente stater, 98055
- Valley Medical Center
-
Yakima, Washington, Forente stater, 98902
- North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
-
-
West Virginia
-
Huntington, West Virginia, Forente stater, 25701
- Edwards Comprehensive Cancer Center
-
Morgantown, West Virginia, Forente stater, 26505
- Monongalia Hospital
-
-
Wisconsin
-
Eau Claire, Wisconsin, Forente stater, 54701
- Marshfield Medical Center-EC Cancer Center
-
Marshfield, Wisconsin, Forente stater, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, Forente stater, 53215
- Aurora Saint Luke's Medical Center
-
Minocqua, Wisconsin, Forente stater, 54548
- Marshfield Medical Center - Minocqua
-
Rice Lake, Wisconsin, Forente stater, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Forente stater, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Weston, Wisconsin, Forente stater, 54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids, Wisconsin, Forente stater, 54494
- Marshfield Clinic - Wisconsin Rapids Center
-
-
-
-
-
San Juan, Puerto Rico, 00917
- San Juan Community Oncology Group
-
San Juan, Puerto Rico, 00927
- Centro Comprensivo de Cancer de UPR
-
San Juan, Puerto Rico, 00936
- San Juan City Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Patients undergoing treatment for cancer types with commercially available therapies.
Beskrivelse
Inclusion Criteria:
-
Is consistent with OR has been diagnosed with one of the following:
-
Colorectal cancer: stage IV
-
Non-small cell or small cell lung cancer: stage III/IV
-
Prostate cancer: metastatic prostate cancer
-
Gastric cancer, not otherwise specified (NOS): stage IV
-
Esophageal cancer, NOS: stage IV
-
Adenocarcinoma of gastroesophageal junction: stage IV
-
High grade serous ovarian cancer: stage III/IV
-
Invasive breast carcinoma: stage III/IV
-
Melanoma: stage III/IV
-
Acute myeloid leukemia
-
Multiple myeloma
-
For the purposes of this study,
- Re-staging is allowed
- Having more than one primary cancer is allowed, if the patient is being treated solely for one of the eligible cancers listed above
-
-
-
Patient should fit in one of the following four clinical scenarios (a-d)
- Undergoing diagnostic workup for one of the diseases listed for which treatment will likely include a new regimen of standard of care therapy OR
- Scheduled to begin treatment with a new regimen of standard of care therapy OR
- Currently progressing on a regimen of standard of care therapy OR
- Currently being treated with a regimen standard of care therapy, without evidence of progression
-
Requirements for fresh tissue biospecimen collections at enrollment:
-
For clinical scenarios a, b, and c above, freshly collected tumor tissue or bone marrow (BM) aspirate must be submitted at enrollment
-
For clinical scenarios a and b, the fresh tissue collection must be prior to starting therapy
-
For clinical scenario a, the biospecimen collection must be part of a standard of care medical procedure
-
For clinical scenarios b or c, the biospecimen collection may be part of a standard of care medical procedure OR
-
The biospecimen collection may be part of a study-specific procedure ("research only biopsy"), when the patient has a tumor amenable to image guided or direct vision biopsy and is willing and able to undergo a tumor biopsy for molecular profiling
- Note: For research-only biopsies, the biopsy must not be associated with a significant risk of severe or major complications or death; the procedure cannot be a mediastinal, laparoscopic, open or endoscopic biopsy; nor can the procedure be a brain biopsy; nor can the patient be under the age of majority as determined by each U.S. state
-
-
-
Requirements for archival tissue:
-
For clinical scenarios a and b above, archival tissue as outlined below must be submitted IF AVAILABLE
-
For clinical scenarios c and d above, archival tissue as outlined below is REQUIRED
-
Pre-existing archival material (formalin-fixed, paraffin-embedded [FFPE] block, BM aspirate, or unstained slides) that:
- Contains the cancer type for which the participant is enrolled, and
- Was collected no more than 5 years prior to initiation of therapy, and
- Contains at least a surface area of 5 mm^2 and optimal surface area of 25 mm^2 or 3-5 mL cryopreserved bone marrow aspirate to yield 200 million bone marrow mononuclear cells, and
- Contains at least 10% tumor content. 70% tumor content is optimal, and
- No more than 1 line of standard of care systemic therapy was administered from the date of archival material collection to the date of initiation of therapy
-
-
Requirements for blood collection: ALL scenarios require fresh blood collection at enrollment
- Blood collection for clinical scenarios a, b, and c must take place within 1 week of fresh tumor specimen collection
- Blood collection for clinical scenario d must take place within 4 weeks of enrollment, and while patient is on treatment
-
Age 13 or older
-
Any sex
-
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2
-
Ability to understand and willingness to sign an informed consent document. Consent may be provided by a Legally Authorized Representative (LAR) in accordance with 45 CFR 46.102(i)
-
NCI PDMR INCLUSION CRITERIA: Patients with CRC with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) status
-
NCI PDMR INCLUSION CRITERIA: Patients with CRC who are 40 years old or younger at time of collection irrespective of mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) status
-
NCI PDMR INCLUSION CRITERIA: Patients with BRCA that are either
- Any race/ethnicity with hormone receptor positive (ER+PR+, ER+PR-, or ER-PR+)
- African American with triple negative (ER-PR-HER2-)
-
NCI PDMR INCLUSION CRITERIA: Patients with lung cancer (LCA), prostate cancer (PCA), gastroesophageal cancer (GEC), ovarian cancer (OV), acute myeloid leukemia (AML), multiple myeloma (MML)
Exclusion Criteria:
-
Treated with or has already begun treatment with a non-standard of care therapeutic agent (investigational) in an interventional clinical trial
- For the purposes of this study, past enrollment in clinical trials whereby the patient was randomized and treated with standard-of-care anti-cancer treatment (chemotherapy regimen, surgery and radiation therapy) is allowed
-
Uncontrolled intercurrent illness that in the physician's assessment would pose undue risk for biopsy
-
Use of full dose coumarin-derivative anticoagulants such as warfarin are prohibited. Patients may be switched to low molecular weight (LMW) heparin at physician discretion
-
Low molecular weight (LMW) heparin is permitted for prophylactic or therapeutic use
-
Factor X inhibitors are permitted
-
Use of anti-platelet drugs are permitted
- Stopping the anticoagulation treatment for biopsy, bone marrow aspirate, or resection should be per site standard operating procedure (SOP)
-
-
NCI PDMR EXCLUSION CRITERIA: Patients with complete response
-
NCI PDMR EXCLUSION CRITERIA: Patients with invasive fungal infections
-
NCI PDMR EXCLUSION CRITERIA: Patients with active and/or uncontrolled infections or who are still recovering from an infection
- Actively febrile patients with uncertain etiology of febrile episode
- All antibiotics for non-prophylactic treatment of infection should be completed at least 1 week (7 days) prior to collection
- No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics
-
NCI PDMR EXCLUSION CRITERIA: Patients with human immunodeficiency virus (HIV), active or chronic hepatitis (i.e. quantifiable hepatitis B virus [HBV]-deoxyribonucleic acid [DNA] and/or positive hepatitis B surface antigen [HbsAg], quantifiable hepatitis C virus [HCV]-ribonucleic acid [RNA]) or known history of HBV/HCV without documented resolution
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Observational (biospecimen collection, chart review)
Patients undergo collection of tissue samples during baseline and at time of disease progression and collection of blood samples throughout the study, including at time of disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected if available. Additionally, patients may undergo CT, PET/CT and/or MRI throughout the study, and may undergo paracentesis on study. Patient medical records are reviewed, and data is collected for at least 5 years. |
Undergo CT
Andre navn:
Undergo MRI
Andre navn:
Undergo PET/CT
Andre navn:
Undergo collection of blood, tissue, bone marrow, and cerebral spinal fluid samples
Andre navn:
Medical charts are reviewed and data is collected
Andre navn:
Undergo paracentesis |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Procure, store and distribute longitudinal biospecimens and associated clinical data
Tidsramme: Up to 10 years
|
Will procure, store and distribute longitudinal biospecimens and associated clinical data for current and future cancer research in order to elucidate molecular mechanisms of sensitivity and intrinsic or acquired resistance to standard of care systemic therapies, including immunotherapy. Cases will be grouped according to patient demographics, cancer type and treatment regimen. Statistical analysis will be descriptive and will be analyzed for each Biospecimen Source Site (BSS) as well as study aggregate. |
Up to 10 years
|
|
Percentage of enrolled patients by cancer type and treatment regimen overall
Tidsramme: Until completion of biospecimen collection, up to 3 years
|
Will assess the percentage of enrolled patients by cancer type and treatment regimen overall and those who contribute samples to the Drug Resistance and Sensitivity Network and other approved investigators. Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of minority and underserved study participants accrued
Tidsramme: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of minority and underserved study participants accrued
Tidsramme: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Pan-cancer gene panel tumor next generation sequencing test
Tidsramme: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Cancer Research Data Commons, The Cancer Imaging Archive and database of Genotypes and Phenotypes data contribution
Tidsramme: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of enrolled patients for whom molecular profiling is attempted
Tidsramme: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of enrolled patients for whom molecular profiling results are generated
Tidsramme: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of enrolled patients for whom samples are obtained at each longitudinal timepoint
Tidsramme: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of collected biospecimens that are delivered to the Patient Derived Models Repository
Tidsramme: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Lyndsay N Harris, National Cancer Institute (NCI)
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Kjønnssykdommer
- Sykdommer i det endokrine systemet
- Vaskulære sykdommer
- Kardiovaskulære sykdommer
- Genitale neoplasmer, hanner
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer
- Kjønnssykdommer, mannlige
- Prostata sykdommer
- Mannlige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Tarmsykdommer
- Sykdommer i immunsystemet
- Sykdommer i luftveiene
- Neoplasmer etter histologisk type
- Gastrointestinale neoplasmer
- Neoplasmer i fordøyelsessystemet
- Sykdommer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Magesykdommer
- Intestinale neoplasmer
- Rektale sykdommer
- Kjønnssykdommer, kvinner
- Lungesykdommer
- Hematologiske sykdommer
- Neoplasmer i endokrine kjertel
- Neoplasmer i hode og nakke
- Neoplasmer i luftveiene
- Thoracale neoplasmer
- Kolonsykdommer
- Esophageal sykdommer
- Sykdommer i eggstokkene
- Adnexal sykdommer
- Genitale neoplasmer, kvinnelige
- Gonadal lidelser
- Hudsykdommer
- Bryst sykdommer
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Nevroektodermale svulster
- Neoplasmer, kjønnsceller og embryonale
- Neoplasmer, nervevev
- Leukemi, myeloid
- Karsinom, bronkogent
- Bronkiale neoplasmer
- Nevroendokrine svulster
- Neoplasmer, plasmacelle
- Hemostatiske lidelser
- Paraproteinemier
- Blodproteinforstyrrelser
- Hemoragiske lidelser
- Leukemi
- Nevi og melanomer
- Neoplasmer i huden
- Eggledersykdommer
- Brystneoplasmer
- Hud- og bindevevssykdommer
- Hemic og lymfatiske sykdommer
- Prostatiske neoplasmer
- Neoplasmer i magen
- Lungeneoplasmer
- Kolorektale neoplasmer
- Leukemi, Myeloid, Akutt
- Neoplasmer i spiserøret
- Neoplasmer i eggstokkene
- Karsinom, ikke-småcellet lunge
- Multippelt myelom
- Småcellet lungekarsinom
- Melanom
- Trippel negative brystneoplasmer
- Egglederneoplasmer
- Undersøkelsesteknikker
- Terapeutikk
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og prosedyrer
- Diagnose
- Punkteringer
- Kirurgiske prosedyrer, operativ
- Kjemisteknikker, analytisk
- Spektrumanalyse
- Drenering
- Prøvehåndtering
- Magnetisk resonansspektroskopi
- Paracentesis
Andre studie-ID-numre
- NCI-2020-00750
- NCI-2020-00750 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
- 10323 (Annen identifikator: CTEP)
- 10323 (Annen identifikator: Division of Cancer Treatment and Diagnosis)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .